ImmuPharma (LON:IMM) Trading 23.5% Higher – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price traded up 23.5% during mid-day trading on Friday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 4.32 ($0.05). 86,096,039 shares were traded during trading, an increase of 204% from the average session volume of 28,338,043 shares. The stock had previously closed at GBX 3.50 ($0.04).

ImmuPharma Price Performance

The firm’s fifty day moving average price is GBX 1.44 and its 200-day moving average price is GBX 1.65. The company has a market capitalization of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Further Reading

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.